Recent meta-analyses revealed that PDE5 inhibitors improve pulmonary hemodynamics and clinical outcomes in systolic heart failure patients with pulmonary hypertension [25,26]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.